XML 90 R53.htm IDEA: XBRL DOCUMENT v3.24.0.1
Collaborative Arrangements - Narrative (Details)
$ in Millions
 1 Months Ended 12 Months Ended
Jan. 31, 2024
USD ($)
Nov. 30, 2021
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Oct. 31, 2023
USD ($)
antibodyDrugConjugate
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Amortization expense for intangible assets     $ 2,000 $ 2,100 $ 1,600  
Research and development     30,531 13,548 12,245  
Licenses and other            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Intangible assets     3,212 3,554    
Lynparza | Licenses and other | Licenses and other            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Intangible assets     1,500      
Lenvima | Licenses and other | Licenses and other            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Intangible assets     683      
Adempas | Licenses and other | Licenses and other            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Intangible assets     526      
Verquvo | Licenses and other            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Intangible assets     52      
Alliance Revenue-Reblozyl | Operating Segments | Pharmaceutical segment            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Revenue from collaborative arrangement     212 166 17  
AstraZeneca            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Amortization expense for intangible assets       250    
AstraZeneca | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Revenue from collaborative arrangement     1,296 1,170 1,018  
Research and development     79 106 120  
AstraZeneca | Lynparza | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Milestone payments sales-based       400    
Probable contingent payments       600    
Liabilities       600    
Sales milestone payments     2,100      
Regulatory milestone payments     105 250    
Aggregate, regulatory milestones payments, maximum     850      
AstraZeneca | Lynparza | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Subsequent Event            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Regulatory milestone payments $ 245          
Eisai            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Amortization expense for intangible assets     154      
Eisai | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Revenue from collaborative arrangement     960 876 704  
Research and development     66 136 173  
Eisai | Lenvima | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Milestone payments sales-based     125 600 200  
Probable contingent payments     250      
Liabilities     250      
Sales milestone payments     2,300      
Regulatory milestone payments       50 75  
Eisai | Lenvima | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Sales-Based Milestones            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Liabilities     125      
Bayer AG | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Milestone payments sales-based       400    
Amortization expense for intangible assets         153  
Revenue from collaborative arrangement     367 341 342  
Research and development     $ 90 75 $ 53  
Bristol Myers Squibb | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Royalty rate, percentage   22.00%        
Bristol Myers Squibb | Licensing Agreements            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Royalty rate, deduction, percentage     50.00%      
Bristol Myers Squibb | Licensing Agreements | Minimum            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Royalty rate, percentage     20.00%      
Bristol Myers Squibb | Licensing Agreements | Maximum            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Royalty rate, percentage     24.00%      
Bristol Myers Squibb | Licensing Agreements | Sales-Based Milestones            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Contingent proceeds from collaborative arrangement     $ 80      
Bristol Myers Squibb | Licensing Agreements | Regulatory Milestones            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Proceeds from collaborators       $ 20    
Daiichi Sankyo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Number of antibody drug conjugates obtained right and obligations | antibodyDrugConjugate           3
Aggregate upfront payments due           $ 4,000
Refundable upfront payments           1,000
Maximum aggregate contingent milestone payments, per product           $ 5,500
Royalty percentage           5.00%
Research and development     5,500      
Daiichi Sankyo | Patritumab Deruxtecan and Ralduotatug Deruxtecan | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Aggregate upfront payments due upon lapse of time     $ 1,500      
Daiichi Sankyo | Patritumab Deruxtecan | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Refundable upfront payments           $ 500
Aggregate upfront payments due upon lapse of time           750
Daiichi Sankyo | Raludotatug Deruxtecan | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Aggregate upfront payments due upon lapse of time           $ 750
Liable contracted portion amount of research and development expenses to incur costs for, percentage           75.00%
Liable contracted portion amount of research and development expenses to incur costs for           $ 2,000
Liable contracted portion amount of excess research and development expenses to incur costs for, percentage           50.00%
Daiichi Sankyo | Ifinatamab Deruxtecan | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Refundable upfront payments           $ 500